| scholarly article | Q13442814 |
| P50 | author | Anne Eckert | Q40650313 |
| P2093 | author name string | Ravid R | |
| Brunner P | |||
| Müller-Spahn F | |||
| Jockers R | |||
| Savaskan E | |||
| Fraschini F | |||
| Angeloni D | |||
| Sözer-Topcular N | |||
| P433 | issue | 4 | |
| P921 | main subject | Alzheimer's disease | Q11081 |
| melatonin | Q180912 | ||
| P304 | page(s) | 311-316 | |
| P577 | publication date | 2006-10-01 | |
| P1433 | published in | European Journal of Histochemistry | Q2192188 |
| P1476 | title | Pineal and cortical melatonin receptors MT1 and MT2 are decreased in Alzheimer's disease | |
| P478 | volume | 50 |
| Q64261566 | Activation of MT2 receptor ameliorates dendritic abnormalities in Alzheimer's disease via C/EBPα/miR-125b pathway |
| Q38629788 | Cerebrospinal Fluid Aβ42 Levels: When Physiological Become Pathological State. |
| Q35561050 | Convergence of melatonin and serotonin (5-HT) signaling at MT2/5-HT2C receptor heteromers |
| Q48088836 | Epigenetic regulation of melatonin receptors in neuropsychiatric disorders. |
| Q36716041 | Gene and protein patterns of potential prion-related markers in the central nervous system of clinical and preclinical infected sheep |
| Q39178920 | Mechanisms of Melatonin in Alleviating Alzheimer's Disease |
| Q34416921 | Melatonin and its agonist ramelteon in Alzheimer's disease: possible therapeutic value |
| Q61812287 | Melatonin receptor stimulation by agomelatine prevents Aβ-induced tau phosphorylation and oxidative damage in PC12 cells |
| Q90456974 | Melatonin receptors limit dopamine reuptake by regulating dopamine transporter cell-surface exposure |
| Q36790172 | Melatonin receptors, heterodimerization, signal transduction and binding sites: what's new? |
| Q41952507 | Melatonin signaling in mouse cerebellar granule cells with variable native MT1 and MT2 melatonin receptors |
| Q28075345 | Melatoninergic System in Parkinson's Disease: From Neuroprotection to the Management of Motor and Nonmotor Symptoms |
| Q37253704 | Microtubules modulate melatonin receptors involved in phase-shifting circadian activity rhythms: in vitro and in vivo evidence |
| Q38809649 | Monoaminergic neuropathology in Alzheimer's disease |
| Q58914961 | Neurobiology, pathophysiology, and treatment of melatonin deficiency and dysfunction |
| Q47557441 | New perspectives on the role of melatonin in human sleep, circadian rhythms and their regulation |
| Q55256658 | Palmitoylation as a Functional Regulator of Neurotransmitter Receptors. |
| Q37198579 | Pharmacological Treatment of Alzheimer's Disease: Is it Progressing Adequately? |
| Q34804952 | Potency of melatonin in living beings |
| Q38243554 | Promising Role of Melatonin as Neuroprotectant in Neurodegenerative Pathology |
| Q46584505 | Role of melatonin receptors in the effects of melatonin on BDNF and neuroprotection in mouse cerebellar neurons |
| Q37434418 | The end of a myth: cloning and characterization of the ovine melatonin MT(2) receptor. |
| Q37992626 | The hormonal Zeitgeber melatonin: role as a circadian modulator in memory processing. |
| Q33823742 | The inhibition of apoptosis by melatonin in VSC4.1 motoneurons exposed to oxidative stress, glutamate excitotoxicity, or TNF-alpha toxicity involves membrane melatonin receptors |
| Q37007350 | The melatonergic system in mood and anxiety disorders and the role of agomelatine: implications for clinical practice |
| Q53396094 | The neuroprotective role of melatonin in neurological disorders. |
| Q37404821 | Unveiling the role of melatonin MT2 receptors in sleep, anxiety and other neuropsychiatric diseases: a novel target in psychopharmacology |
Search more.